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OBJECTIVE: Approximately 700,000 people in Spain
are infected with HBV. The medical costs associated with
chronic HBV have not yet been studied in Spain. This
research aims to estimate the treatment patterns of 
major HBV health states and their associated costs.
METHODS: Resource use patterns were determined by
a panel of physicians caring for HBV patients in three
hospitals using a questionnaire. A review of the literature
on the cost of the disease was also carried out. Average
values of health resource utilisation were computed for
patients with chronic hepatitis B (CHB), compensated
and decompensated cirrhosis (CC and DC), hepatocellu-
lar carcinoma (HC) and liver transplantation (LT). Unit
costs were derived from the Soikos health unit costs data-
base. RESULTS: No variations in clinical practice were
detected among the experts consulted. The estimated
annual cost is €3396 for CHB (€8493 if treated with
antiviral therapy -33% patients- and €850 for patients
without antivirals). Estimated annual cost for CC is
€3997 (€7486 if treated with antiviral therapy -50%
patients- and €510 for patients without antivirals).
Average annual cost of DC (including ascites, bacterial
peritonitis, variceal haemorrhage and hepatic enceph-
alopathy) is €6851. Hepatocellular carcinoma costs
€3,731 annually with few patients receiving chemother-
apy. Liver transplantation was estimated to cost €25,165
for the transplantation phase and €5,770 in the ﬁrst year
post transplant. CONCLUSIONS: The results obtained,
although not fully representative for Spain due to the
small number of hospitals sampled, show that the costs
associated with chronic HBV are signiﬁcant. The most
severe stages such as episodes of decompensated cirrho-
sis and transplantation are the major cost drivers. Adopt-
ing therapies that slow or stop disease progression could
reduce morbidity and mortality and also the cost burden
to the health care system.
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OBJECTIVE: In this study, cost-effectiveness of the 23-
valent pneumococcal vaccination was assessed in Cat-
alonia (Spain). METHODS: Cost-effectiveness was
measured in terms of cost per life year gained (LYG), com-
paring net program costs and effectiveness. The net
program cost was calculated from vaccinating cost less
reduced health care costs from pneumococcal pneumo-
nia. Vaccination costs were calculated taking into account
a price per vaccine of €11.51. Costs and beneﬁts were esti-
mated for the period 1996–2001 using a 5% discount
rate. RESULTS: The cost-effectiveness was €9,023 per
LYG for the universal vaccination of individuals aged >5
years, €113,177 per LYG in individuals aged 5–24 years,
€19,482 per LYG in those aged 25–44 years, €7,123 per
LYG in those aged 45–64 years and €-4,442 per LYG in
those aged >64 years. Results were sensitive to the vaccine
price and efﬁcacy, and the percentage of pneumonias
caused by S. pneumoniae. Multiway sensitivity analysis
showed that, in individuals aged >64 years, the vaccine
was cost-effective for vaccine efﬁcacy >45% when the
percentage of pneumonias caused by S. pneumoniae of
20%, >30% for a percentage of 30% and >25% for a
percentage of 40%, and when efﬁcacy was >30% for the
current price per vaccine, >40% for a price of €15, and
>50% for a price of €20. In individuals aged 45–64 years,
the cost-effectiveness was <€30,000/LYG when vaccine
efﬁcacy was >80% for a percentage of pneumonias
caused by S. pneumoniae of 20%, >60% for a percent-
age of 30% and >40% for a percentage of 40%. The cost-
effectiveness was <€30,000/LYG when efﬁcacy was >30%
for the current price, >50% for a price of €15, and >70%
for a price of €20. CONCLUSION: Results obtained in
this study shows that pneumococcal vaccination should
be a priority preventive intervention in individuals aged
>64 and 45–64 years.
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OBJECTIVE: In order to increase case-detection of
Chlamydia trachomatis (CT) in a multicultural, low-
income and high-CT-prevalence neighbourhood a novel
approach was piloted in collaboration with the pharmacy
of the health centre. The objective of this study is to esti-
mate cost-effectiveness of the approach. METHODS:
During a 2-year period, women aged 15–29yrs. who col-
lected their contraceptives at the pharmacy were offered
CT-test materials. Home-collected urine could be mailed
to the laboratory and the General Practitioner received
the results. RESULTS: Nine percent of respondents were
CT-positive (14% among 15–24yr). There was a strong
association with Surinamese/Antillean background.
Uptake of the programme was low (27%). Net cost per
PID prevented ranged from cost-saving up to €3872 in a
low complication rate scenario. CONCLUSIONS: Faced
